INmune Bio, Inc.

NASDAQ:INMB

Biotechnology

Healthcare
$1.89 +8.38%

+$0.15 today

Market cap
$50.25M
Beta
0.98
P/E (TTM)
-1.1
EPS (TTM)
-$1.56
52W Low $1.09High $3.24

Volume 0.09M

Average 0.68M

INMB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

INmune Bio, Inc.NASDAQ: INMB

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $1.5M fell 27.9% year over year, ahead of the -107.3% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +11.5% a year.

Context

  • Stock-based compensation amounted to 19820.0% of revenue in FY2025, down 34501.4 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -27.9% holds above the trailing-twelve-month pace of -107.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.5M+122.7% QoQ
Last fiscal yearDec 2025
$9.91M+30.3% YoY
LTMMar 2026
-$579K-107.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.9%——
1 year+30.3%——
3-year CAGR+11.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.91M USD
Year-over-year change
+30.3%
4-year CAGR
+19.9%

Stock-Based Compensation vs competitors

How INMB compares with its peers on the latest reported figures

  • INMB's LTM Mar 2026 stock-based compensation of $579K is the smallest of the 4 companies compared; the peer median is $3.78M.
  • Its year-over-year change of -107.3% is the 3rd highest of 4, against a peer median of +38.1%.
  • Over three fiscal years its annual growth of +11.5% compares with a peer median of +523.5%.
INMB Competitors Peer median
Stock-Based Compensation for INMB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$1.79B -27809.6%+824.6%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026$11.67M +86.0%+523.5%—
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$3.78M +38.1%-6.1%41.9%
INMBINmune Bio, Inc.LTM Mar 2026$579K -107.3%+11.5%—
Peer median (excluding INMB) $3.78M+38.1%+523.5%41.9%

Competitors are the stored peer set for INMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Depreciation & Amortization000084K
Deferred Income Tax00000
Stock-Based Compensation4.8M7.15M7.37M7.61M9.91M
Change in Working Capital(3.09M)(2.86M)10.44M1.04M(2.53M)
Accounts Receivables(3.71M)(2.96M)6.02M1.03M(3.13M)
Inventory3.71M2.96M000
Accounts Payables2.26M1.4M2.72M(1.37M)1.86M
Other Working Capital(5.35M)(4.27M)1.7M1.38M(1.25M)
Other Non-Cash Items126K328K224K79K15.89M
Operating Cash Flow(28.5M)(22.69M)(11.98M)(33.36M)(22.58M)
Capital Expenditures(15M)000(1.04M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(15M)000(1.04M)
Debt Repayment14.95M0(5M)(10M)0
Common Stock Issued80.25M699K775K27.79M27.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.15M30K0422K0
Financing Cash Flow96.36M729K(4.23M)18.21M27.61M
Effect of Forex Changes(10K)(700K)(100K)224K(159K)
Net Change in Cash52.84M(22.66M)(16.31M)(14.93M)3.83M
Free Cash Flow(43.5M)(22.69M)(11.98M)(33.36M)(23.62M)

INmune Bio, Inc.

NASDAQ:INMB

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.